Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Promising combo for advanced cancers hits snag: trial terminated early

NCT ID NCT04916002

First seen Jan 08, 2026 · Last updated May 21, 2026 · Updated 22 times

Summary

This study tested whether combining two drugs—vidutolimod (injected into tumors) and cemiplimab (given through a vein)—could shrink or control advanced cancers like Merkel cell carcinoma, skin cancer, breast cancer, lung cancer, and throat cancer. The trial enrolled 77 adults and planned to give treatment for up to 2 years, but it was terminated early. The main goal was to see how many patients' tumors responded, and to check safety. Because lifelong medication may be needed, this is considered disease control, not a cure.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • City of Hope

    Duarte, California, 91010, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Dartmouth Clinical Trial Office

    Lebanon, New Hampshire, 03756, United States

  • East Carolina University

    Greenville, North Carolina, 27858, United States

  • Fiona Stanley Hospital

    Murdoch, Western Australia, 6150, Australia

  • GenesisCare USA

    Jacksonville, Florida, 32204, United States

  • Karmanos Cancer Institute

    Detroit, Michigan, 48201, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Norton Cancer Institute

    Louisville, Kentucky, 40202, United States

  • OU Health Stephenson Cancer Center

    Oklahoma City, Oklahoma, 73104, United States

  • Ohio State University

    Columbus, Ohio, 43210, United States

  • Oncology Consultants

    Houston, Texas, 77030, United States

  • Orlando Health Cancer Institute

    Orlando, Florida, 32806, United States

  • Peter MacCallum Cancer Centre (PMCC) and The Royal Melbourne Hospital

    Melbourne, Victoria, 3050, Australia

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, 4102, Australia

  • St. Vincent's Hospital

    Darlinghurst, New South Wales, 2010, Australia

  • UC San Diego Moores Cancer Center

    La Jolla, California, 92037-0845, United States

  • University of Alabama

    Birmingham, Alabama, 35294, United States

  • University of California

    Los Angeles, California, 90095, United States

  • University of Iowa

    Iowa City, Iowa, 52242, United States

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania, 15232, United States

  • University of Utah Huntsman Cancer Center

    Salt Lake City, Utah, 84112, United States

  • University of Washington

    Seattle, Washington, 98109, United States

  • VA Maryland Health Care System

    Baltimore, Maryland, 20814, United States

Conditions

Explore the condition pages connected to this study.